Healthcare provider profile · identity verified

Jeffrey Sweers, MD

Family Practice · MARQUETTE, MI · NPI 1982139929

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	298	74
Lisinopril	Lisinopril	198	52
Eliquis	Apixaban	173	22
Omeprazole	Omeprazole	172	36
Levothyroxine Sodium	Levothyroxine Sodium	167	41
Gabapentin	Gabapentin	140	20
Metoprolol Succinate	Metoprolol Succinate	131	35
Amlodipine Besylate	Amlodipine Besylate	116	32
Losartan Potassium	Losartan Potassium	108	30
Simvastatin	Simvastatin	105	27
Furosemide	Furosemide	96	28
Sertraline Hcl	Sertraline Hcl	92	18
Metoprolol Tartrate	Metoprolol Tartrate	88	18
Carvedilol	Carvedilol	72	17
Clopidogrel	Clopidogrel Bisulfate	71	17
Tamsulosin Hcl	Tamsulosin Hcl	67	21
Hydrochlorothiazide	Hydrochlorothiazide	62	18
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	62	12
Albuterol Sulfate Hfa	Albuterol Sulfate	58	28
Fluticasone Propionate	Fluticasone Propionate	55	28
Donepezil Hcl	Donepezil Hcl	49	suppressed
Tramadol Hcl	Tramadol Hcl	48	suppressed
Buspirone Hcl	Buspirone Hcl	47	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	47	14
Metformin Hcl	Metformin Hcl	46	16
Meloxicam	Meloxicam	44	22
Allopurinol	Allopurinol	41	13
Metformin Hcl Er	Metformin Hcl	41	14
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	39	13
Quetiapine Fumarate	Quetiapine Fumarate	36	suppressed
Solifenacin Succinate	Solifenacin Succinate	35	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	35	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	34	suppressed
Memantine Hcl	Memantine Hcl	33	suppressed
Prednisone	Prednisone	33	20
Alendronate Sodium	Alendronate Sodium	32	11
Spironolactone	Spironolactone	32	suppressed
Bupropion Xl	Bupropion Hcl	31	suppressed
Pravastatin Sodium	Pravastatin Sodium	31	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	30	14
Potassium Chloride	Potassium Chloride	29	11
Montelukast Sodium	Montelukast Sodium	28	12
Famotidine	Famotidine	27	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	27	11
Breo Ellipta	Fluticasone/Vilanterol	26	suppressed
Linzess	Linaclotide	26	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	25	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	25	12
Carbamazepine Er	Carbamazepine	24	suppressed
Finasteride	Finasteride	24	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	24	suppressed
Jardiance	Empagliflozin	24	suppressed
Xeljanz Xr	Tofacitinib Citrate	24	suppressed
Duloxetine Hcl	Duloxetine Hcl	23	suppressed
Lovastatin	Lovastatin	23	suppressed
Cephalexin	Cephalexin	21	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	21	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	21	suppressed
Warfarin Sodium	Warfarin Sodium	21	suppressed
Olanzapine	Olanzapine	20	suppressed
Pregabalin	Pregabalin	20	suppressed
Trazodone Hcl	Trazodone Hcl	20	suppressed
Minocycline Hcl	Minocycline Hcl	19	suppressed
Risperidone	Risperidone	19	suppressed
Xarelto	Rivaroxaban	19	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	19	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	18	18
Nitroglycerin	Nitroglycerin	18	16
Ropinirole Hcl	Ropinirole Hcl	18	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	18	14
Mirtazapine	Mirtazapine	17	suppressed
Nystatin	Nystatin	17	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	17	suppressed
Ventolin Hfa	Albuterol Sulfate	17	suppressed
Ezetimibe	Ezetimibe	16	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	16	suppressed
Naproxen	Naproxen	16	suppressed
Nifedipine Er	Nifedipine	16	suppressed
Paroxetine Hcl	Paroxetine Hcl	16	suppressed
Synthroid	Levothyroxine Sodium	16	suppressed
Atenolol	Atenolol	15	suppressed
Dofetilide	Dofetilide	15	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	15	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	15	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	15	suppressed
Valsartan	Valsartan	15	suppressed
Comfort Ez Pen Needle	Pen Needle, Diabetic	14	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	14	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Celecoxib	Celecoxib	13	suppressed
Enalapril Maleate	Enalapril Maleate	13	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	13	suppressed
Glipizide	Glipizide	13	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	13	suppressed
Carbidopa-Levodopa Er	Carbidopa/Levodopa	12	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	12	suppressed
Diazepam	Diazepam	12	suppressed
Glimepiride	Glimepiride	12	suppressed
Incruse Ellipta	Umeclidinium Bromide	12	suppressed
Invega Sustenna	Paliperidone Palmitate	12	suppressed
Loperamide	Loperamide Hcl	12	suppressed
Nebivolol Hcl	Nebivolol Hcl	12	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	11	suppressed
Cosentyx Sensoready Pen	Secukinumab	11	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	11	suppressed
Humalog Kwikpen U-100	Insulin Lispro	11	suppressed
Methotrexate	Methotrexate Sodium	11	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	11	suppressed
Mounjaro	Tirzepatide	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Praluent Pen	Alirocumab	11	suppressed
Topiramate	Topiramate	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed
Vilazodone Hcl	Vilazodone Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error